|Bid||55.02 x 900|
|Ask||55.00 x 1000|
|Day's Range||52.43 - 55.26|
|52 Week Range||25.18 - 61.23|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 21, 2021 - Apr 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.56|
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...
Good afternoon, ladies and gentlemen, and welcome to the Fourth Quarter 2020 Earnings Conference Call for Merit Medical Systems, Inc. At this time, all participants have been placed in listen-only mode. Thank you, Liz, and welcome, everyone, to Merit Medical's Fourth Quarter 2020 Earnings Conference Call.
Shares of Merit Medical Systems (NASDAQ:MMSI) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 35.00% year over year to $0.54, which beat the estimate of $0.43. Revenue of $258,004,000 up by 0.03% year over year, which beat the estimate of $250,450,000. Outlook The upcoming fiscal year's EPS expected to be between $1.84 and $1.98. The upcoming fiscal year's revenue expected to be between $990,000,000 and $1,010,000,000. Conference Call Details Date: Feb 24, 2021 View more earnings on MMSI Time: 05:00 PM ET Webcast URL: https://edge.media-server.com/mmc/p/cxg5cavx Technicals Company's 52-week high was at $61.23 52-week low: $25.18 Price action over last quarter: Up 9.44% Company Profile Merit Medical Systems, Inc. is a South Jordan, Utah, based medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm currently reports through two overarching units, Cardiovascular (96% of 2018 revenue) and Endoscopy (4%). From a geographic perspective the firm is U.S. centric, with domestic sales accounting for approximately 55% of 2018 revenue and international sales making up the remaining 45%. See more from BenzingaClick here for options trades from BenzingaEarnings Preview for Merit Medical Systems© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.